Enzon to Sell Specialty Business to Sigma-Tau

Enzon Pharmaceuticals, Inc. announced that it has entered into a definitive agreement to sell its specialty pharmaceutical business to the sigma-tau Group for $300 million plus an additional amount of up to $27 million based on success milestones.
RTTNews